Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 May 3;19(1):105.
doi: 10.1186/s12882-018-0885-6.

The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial)

Line Aas Mortensen  1   2 , Helle C Thiesson  3   4 , Birgitte Tougaard  5 , Martin Egfjord  6 , Anne Sophie Lind Fischer  7 , Claus Bistrup  3   4
Affiliations
Randomized Controlled Trial

The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial)

Line Aas Mortensen et al. BMC Nephrol. .

Abstract

Background: Calcineurin inhibitor induced nephrotoxicity contributes to late allograft failure in kidney transplant patients. Evidence points towards aldosterone to play a role in the development of fibrosis in multiple organs. Animal studies have indicated a beneficial effect of mineralocorticoid receptor antagonists preventing calcineurin inhibitor induced nephrotoxicity. Only few studies have explored this effect in humans. The objective of this study is to evaluate the effect of spironolactone on glomerular filtration rate and fibrosis in kidney transplant patients.

Method: Prospective, double-blind, randomized, clinical trial including 170 prevalent kidney transplant patients. Patients are randomized to spironolactone 25-50 mg/day or placebo for three years. Primary outcome is glomerular filtration rate evaluated by chrome-EDTA clearance. Secondary outcomes are 24-h protein excretion, amount of interstitial fibrosis in renal allograft biopsies, and cardiovascular events. As an exploratory outcome, we aim to identify markers of fibrosis in blood and urine.

Discussion: Long term allograft survival remains a key issue in renal transplantation, partly due to calcineurin inhibitor induced nephrotoxicity. Evidence from animal- and small human studies indicate a beneficial effect of mineralocorticoid receptor antagonism on renal function and fibrosis. This study aims to test this hypothesis in a sufficiently powered randomized clinical trial. Results might influence the future management of long term allograft survival in renal transplantation.

Trial registration: ClinicalTrials.gov identifier (05/17/2012): NCT01602861 . EudraCT number (05/31/2011): 2011-002243-98.

Keywords: Aldosterone; Cyclosporine A; Fibrosis; Glomerular filtration rate; IFTA; Kidney transplantation; Mineralocorticoid; Tacrolimus.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The SPIREN trial has been approved by the Research Ethics Committee of Southern Denmark on the 24th of August 2011 (project ID: s-20110095, protocol version 2 (07/28/2011)). Oral and written informed consent to participation is obtained from all study participants by study personnel prior to any study related procedure. All participants receive both written and oral information about the study before giving consent. The trial is conducted according to the standards of Good Clinical Practice (GCP) and undergoes continuous monitoring by local GCP representatives.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Participant timeline
See this image and copyright information in PMC

References

    1. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, et al. Cyclosporin a in patients receiving renal allografts from cadaver donors. Lancet. 1978;2:1323–1327. doi: 10.1016/S0140-6736(78)91970-0. - DOI - PubMed
    1. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989;2:1000–1004. doi: 10.1016/S0140-6736(89)91014-3. - DOI - PMC - PubMed
    1. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508. - PubMed
    1. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78:557–565. doi: 10.1097/01.TP.0000128636.70499.6E. - DOI - PubMed
    1. Nankivell BJ, P’Ng CH, O'Connell PJ, Chapman JR. Calcineurin inhibitor nephrotoxicity through the Lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation. 2016;100:1723–1731. doi: 10.1097/TP.0000000000001243. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data